WALTHAM, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has published its Environmental, Social and Governance (ESG) report for 2025. As a company focused on optimizing meaningful engagement opportunities at critical junctures of the healthcare journey, we remain dedicated to aligning our mission with our responsibiliti ...

WALTHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Monday, May 12, 2025, at 4:30 p.m. Eastern Time to discuss its results for the first quarter period ended March 31, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the c ...

WALTHAM, Mass., April 18, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that, as part of OptimizeRx’s ongoing process to refresh and expand its board of directors (the “Board”), it intends to appoint a new independent director to its Board of Directors during the second half of this year. With the appointment of a ne ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) | Nevada | 26-1265381 | | --- | --- | | (State or other ...

Financial Data and Key Metrics Changes - Fourth quarter revenue reached $32.3 million, a 14% increase from $28.4 million in the same period of 2023, driven by increased DAAP-related revenue streams [20] - Gross margin improved from 62.9% in Q4 2023 to 68.2% in Q4 2024, attributed to a favorable solution and channel partner mix [20] - Net loss for Q4 2024 was $0.1 million, significantly reduced from a net loss of $4.1 million in Q4 2023 [22] - Non-GAAP net income for Q4 2024 was $5.5 million, or $0.30 per diluted share, compared to $4.6 million, or $0.26 per diluted share in the prior year [22] - Adjusted EBITDA for Q4 2024 was $8.8 million, up from $5.8 million in Q4 2023 [22] Business Line Data and Key Metrics Changes - Average revenue for the top 20 pharmaceutical manufacturers was $2.9 million, a 22% increase year-over-year [24] - The average revenue from the top five customers reached over $9 million in 2024, with plans to elevate at least one more customer to this level in 2025 [13] Market Data and Key Metrics Changes - The net revenue retention rate improved to 121%, up from 105% in the previous year [24] - Revenue per FTE increased to $701,000, compared to $586,000 in the prior year [24] Company Strategy and Development Direction - The company aims to transition to a subscription-based revenue model, particularly for the data component of its DAAP offerings, to enhance revenue predictability and customer retention [16][36] - The strategic focus includes operational excellence, customer centricity, and expanding the unique value proposition with pharmaceutical partners [6][7] - The company is targeting to become a "Rule of 40" company over the next several years, balancing growth and profitability [16][60] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's position in the market, citing strong momentum heading into 2025 and a commitment to under-promise and over-deliver [72] - The company is closely monitoring external factors, including FDA approvals, which could impact the pharmaceutical industry's ability to bring products to market [80] Other Important Information - The company completed the Medicx Health acquisition in Q4 2023, which is expected to drive further growth and operational efficiencies [21] - The total addressable market (TAM) is estimated at $10 billion, indicating significant growth potential in an underpenetrated market [17] Q&A Session Summary Question: Focus on customer centricity and strategy changes - Management emphasized increasing customer centricity and ensuring a pleasurable experience for clients, aiming to make it easier for them to renew and expand their business [30][31] Question: Impact of transitioning to subscription-based revenue - The transition to a subscription model is expected to create more predictable and recurring revenue, with a significant push towards this goal [35][36] Question: Gross margin expansion drivers - Gross margin expansion was driven by product mix, particularly from DAAP-related revenues, and while the current level is high, it may not be sustainable long-term [42][46] Question: Visibility into new deals and backlog - The company reported strong demand for new DAAP deals and improved visibility into contracted revenue for 2025, indicating a positive outlook [50][53] Question: Timeframe for becoming a Rule of 40 company - Management indicated that achieving the Rule of 40 is expected to take 3 to 5 years, with a focus on both top-line growth and EBITDA expansion [58][60] Question: Competitive environment and market dynamics - The competitive landscape is evolving, with new entrants in the DTC space, but the company maintains a strong position due to its unique ability to integrate HCP and DTC marketing [111][112]

OPTIMIZERx Corp. OPRX, a health care technology firm, reported on Wednesday fourth-quarter sales of $32.32 million, up 14% year-over-year, beating the consensus of $30.36 million.The company reported adjusted EPS of 30 cents, beating the analyst’s estimate of 27 cents.Full-year revenue increased 29% year-over-year, reaching $92.1 million. The company’s gross profit climbed 23% in the fourth quarter to $22 million, with full-year gross profit totaling $59.4 million.Adjusted EBITDA demonstrated significant gr ...

Company Performance - OptimizeRx Corp. reported quarterly earnings of $0.30 per share, exceeding the Zacks Consensus Estimate of $0.25 per share, and up from $0.26 per share a year ago, representing an earnings surprise of 20% [1] - The company posted revenues of $32.32 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 9.58%, compared to year-ago revenues of $28.37 million [2] - Over the last four quarters, OptimizeRx has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Outlook - The stock has underperformed, losing about 14.8% since the beginning of the year, while the S&P 500 declined by 5.3% [3] - The current consensus EPS estimate for the coming quarter is -$0.05 on revenues of $21.28 million, and for the current fiscal year, it is $0.35 on revenues of $101.3 million [7] - The estimate revisions trend for OptimizeRx is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Computer - Software industry, to which OptimizeRx belongs, is currently in the top 29% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Performance - Q4 2024 revenue increased 14% year-over-year to $32.3 million, with full year revenue reaching $92.1 million, a 29% increase compared to 2023[3] - Q4 gross profit rose 23% year-over-year to $22.0 million, resulting in a gross margin of 68%[3] - Net revenue for the year ended December 31, 2024, increased to $92,127 million, up from $71,522 million in 2023, representing a growth of 28.8%[23] - Gross profit for the year ended December 31, 2024, was $59,378 million, compared to $42,900 million in 2023, reflecting a 38.4% increase[23] - Adjusted EBITDA for Q4 2024 was $8.8 million, a 53% increase from $5.8 million in Q4 2023, with full year Adjusted EBITDA at $11.7 million[7] - Adjusted EBITDA for the year ended December 31, 2024, was $11,730 million, compared to $3,574 million in 2023, representing a significant increase[29] - Non-GAAP net income for the year ended December 31, 2024, was $6,162 million, up from $4,425 million in 2023, showing a growth of 39.3%[29] Loss and Expenses - GAAP net loss for Q4 2024 was $(0.1) million, or $0.00 per share, while the full year net loss totaled $(20.1) million, or $(1.10) per share[7] - The net loss for the year ended December 31, 2024, was $20,110 million, compared to a net loss of $17,566 million in 2023, indicating a deterioration of 8.8%[23] - Total operating expenses for the year ended December 31, 2024, were $73,084 million, an increase from $69,302 million in 2023, marking a rise of 5.4%[23] - Stock-based compensation for the year ended December 31, 2024, was $11,467 million, down from $13,717 million in 2023, indicating a reduction of 16.4%[26] Cash Flow and Liquidity - Cash and cash equivalents as of December 31, 2024, were $13.4 million, with net cash provided by operating activities at $4.9 million for the year[7] - Cash provided by operating activities for the year ended December 31, 2024, was $4,889 million, a recovery from cash used of $7,240 million in 2023[26] - The company reported a cash and cash equivalents balance of $13,380 million at the end of the period, down from $13,852 million at the beginning of the period[26] Customer and Market Insights - Net revenue retention improved to 121% in 2024, up from 105% in 2023[2] - Average revenue per top 20 pharmaceutical manufacturer increased to $2,933,000 in 2024 from $2,399,000 in 2023[2] - The company generated revenue from 48 DAAP deals in 2024, up from 24 in 2023[3] - The company aims to transition DAAP customers to a subscription-based model to improve margins and reduce business cyclicality[2] Future Outlook - The company expects full year 2025 revenue to be at least $100 million, with Adjusted EBITDA of at least $12 million[5] - The weighted average number of shares outstanding for the year ended December 31, 2024, was 18,292,935, compared to 17,124,801 in 2023, reflecting an increase in shares[23]

Core Insights - OptimizeRx Corp. reported strong financial results for Q4 and full year 2024, exceeding expectations and consensus estimates, with a focus on leveraging its industry leadership to address critical challenges in the pharmaceutical sector [1][5][7] Financial Performance - Q4 revenue reached $32.3 million, a 14% increase year-over-year from $28.4 million in Q4 2023 [4][5] - Full year revenue for 2024 was $92.1 million, representing a 29% increase compared to $71.5 million in 2023 [5][21] - Q4 gross profit increased 23% year-over-year to $22.0 million, with a gross margin of 68% [4][5] - Full year gross profit totaled $59.4 million [5] - Non-GAAP net income for Q4 was $5.5 million, or $0.30 per diluted share, while for the full year it was $6.2 million, or $0.34 per diluted share [5][25] - Adjusted EBITDA for Q4 was $8.8 million, a 53% increase from $5.8 million in Q4 2023 [5][26] Key Performance Indicators - Average revenue per top 20 pharmaceutical manufacturer increased to $2.933 million in 2024 from $2.399 million in 2023 [2] - Net revenue retention improved to 121% in 2024 from 105% in 2023 [2] - The percentage of total revenue attributable to the top 20 pharmaceutical manufacturers was 64% in 2024, down from 67% in 2023 [2] Strategic Outlook - The company aims to achieve at least $100 million in revenue and an Adjusted EBITDA of at least $12 million for the full year 2025 [7] - A strategic focus on transitioning DAAP customers to a subscription-based model is expected to improve margins and reduce business cyclicality [1][5]

Core Points - OptimizeRx Corp. has received a notice from Whetstone Capital Advisors, LLC regarding the nomination of two candidates for the Board of Directors at the 2025 Annual Meeting of Stockholders [1] - The Board of Directors will provide a formal recommendation on the nominations in the definitive proxy statement to be filed with the SEC [2] Company Overview - OptimizeRx is a leading healthcare technology company that connects life science brands with patients and healthcare providers through innovative AI-driven tools [3] - The company focuses on patient-centric technology, ensuring meaningful interactions that deliver therapies to the right patients at the right time [4] Proxy Statement Information - OptimizeRx plans to file proxy materials with the SEC for the 2025 Annual Meeting, including a definitive proxy statement and a WHITE proxy card [6] - Stockholders are encouraged to read the proxy statement and related documents carefully when available, as they will contain important information [7] Participant Information - The company, its directors, and certain executive officers may be deemed "participants" in the proxy solicitation for the 2025 Annual Meeting [8]